Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10573027 | 1.00 | HPGD (0.60) | HPGDMEN1KMT2AMAPTCHRM1 | |
| SCHEMBL5776074 | 1.00 | HPGD (0.60) | HPGDMEN1KMT2AMAPTCHRM1 | |
| SCHEMBL9366034 | 0.98 | HPGD (0.63) | HPGDMEN1KMT2AMAPTCHRM1 | |
| SCHEMBL9366030 | 0.98 | HPGD (0.63) | HPGDMEN1KMT2AMAPTCHRM1 | |
| SCHEMBL6536929 | 0.92 | HPGD (0.51) | HPGDMEN1KMT2AMAPTCHRM1 | |
| SCHEMBL8884084 | 0.83 | RAB9A (0.53) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10419001 | 0.83 | RAB9A (0.53) | HPGDMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL11482052 | 0.82 | HPGD (0.52) | HPGDMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL11482047 | 0.82 | HPGD (0.52) | HPGDMEN1KMT2AALDH1A1USP2 | |
| SCHEMBL5773229 | 0.80 | HPGD (0.50) | HPGDMEN1KMT2AALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119506908-A | Synthesis method of parecoxib sodium intermediate | 四川轻化工大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-104910091-A | Preparation method of anhydrous and non-solvation A crystallization parecoxib sodium | BEIJING HRDX MEDICINAL TECHNOLOGIES CO LTD | 2015-09-16 | — | — | CN | disclosed |
| EP-1054887-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005123701-A1 | METHOD FOR THE PREPARATION OF DIARYLISOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES | PHARMACIA CORPORATION (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6583154-B1 | Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines | AMGEN INC. | 2003-06-24 | — | — | US | disclosed |
| US-6187777-B1 | PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS | AMGEN INC. | 2001-02-13 | — | — | US | disclosed |
| EP-1054887-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999040091-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| US-4886924-A | Stereospecific synthesis of [E]-alkenes from enamines via hydroboration | THE DOW CHEMICAL COMPANY (US) | 1989-12-12 | — | — | US | disclosed |